Kelun-Biotech's SKB378/HBM9378: A Promising Anti-TSLP mAb in Global Licensing Deal

Kelun-Biotech, a leading biopharmaceutical company, has announced an exclusive licensing agreement for SKB378/HBM9378, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb), with Windward Bio AG. This strategic partnership highlights the potential market value and therapeutic promise of SKB378/HBM9378, which targets immunological conditions such as asthma and chronic obstructive pulmonary disease (COPD).



SKB378/HBM9378 is a novel, recombinant fully human mAb that potently binds to the TSLP ligand, inhibiting the TSLP-mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor. This mechanism of action makes it a promising therapeutic candidate for various immunological conditions, including asthma and COPD.

In the case of asthma, TSLP plays a key role in the development and progression of the disease by activating immune cells and promoting inflammation in the airways. By blocking the interaction between TSLP and its receptor, SKB378/HBM9378 can help reduce inflammation and alleviate symptoms in patients with asthma. In fact, inhibition of TSLP has demonstrated benefit in a wide array of inflammatory phenotypes in asthma, highlighting the potential of SKB378/HBM9378 as a therapeutic option for this condition.

Similarly, in COPD, TSLP is involved in the pathogenesis of the disease by promoting inflammation and airway remodeling. By targeting TSLP, SKB378/HBM9378 can help address the unmet needs in COPD by reducing inflammation and preventing the progression of the disease. The extended half-life and effector silencing of SKB378/HBM9378 also provide a favorable dosing advantage, making it a promising candidate for the treatment of COPD.



The licensing agreement with Windward Bio AG has a significant positive impact on Kelun-Biotech's financial outlook and strategic positioning in the biotech industry. The agreement is expected to generate a total of up to US$970 million in upfront and milestone payments, as well as single to double-digit tiered royalties on net sales of SKB378/HBM9378. This substantial financial influx will strengthen Kelun-Biotech's financial position and provide resources for further R&D and expansion.

Moreover, the partnership with Windward Bio, a company led by a highly experienced team with deep discovery, development, and commercialization expertise, provides Kelun-Biotech with valuable resources and know-how to advance its immunology pipeline. The agreement also reflects Kelun-Biotech's commitment to expanding its global presence and strategic partnerships, which will help maximize the value of its pipelines and strengthen its position in the competitive biotech industry.

In conclusion, the exclusive licensing agreement for SKB378/HBM9378 between Kelun-Biotech and Windward Bio AG underscores the potential market value and therapeutic promise of this anti-TSLP mAb. With its unique mechanism of action and the support of a strong partner, SKB378/HBM9378 is well-positioned to address unmet needs in immunological conditions such as asthma and COPD, ultimately improving the lives of patients worldwide.